Gracell Biotechnologies To Present Updated Results From BCMA/CD19 Dual-Targeting FasTCAR-T GC012F In Newly Diagnosed Multiple Myeloma At The 65 American Society Of Hematology Annual Meeting & Exposition
Portfolio Pulse from Benzinga Newsdesk
Gracell Biotechnologies Inc. (NASDAQ:GRCL) will present updated results from its ongoing Phase 1 investigator-initiated study of GC012F, a FasTCAR-enabled BCMA and CD19 dual-targeting autologous cell therapy, at the 65th American Society of Hematology Annual Meeting & Exposition. The therapy is being evaluated for hematologic malignancies and autoimmune disease. The updated results include longer-term follow-up and data from additional patients in the study. Gracell believes that GC012F has the potential to revolutionize the treatment landscape for multiple myeloma patients.
November 02, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gracell Biotechnologies is set to present updated results from its Phase 1 study of GC012F, a therapy being evaluated for hematologic malignancies and autoimmune disease. The company believes this could revolutionize treatment for multiple myeloma patients.
The news of Gracell Biotechnologies presenting updated results from its Phase 1 study of GC012F is directly related to the company and its ongoing research. The positive outlook expressed by the company regarding the potential of the therapy to revolutionize treatment for multiple myeloma patients could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100